Enfusion Stock Buy Hold or Sell Recommendation
| ENFN Stock | USD 9.94 0.08 0.80% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Enfusion is 'Strong Buy'. The recommendation algorithm takes into account all of Enfusion's available fundamental, technical, and predictive indicators you will find on this site.
Check out Enfusion Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide. In addition, we conduct extensive research on individual companies such as Enfusion and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
Enfusion |
Execute Enfusion Buy or Sell Advice
The Enfusion recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Enfusion. Macroaxis does not own or have any residual interests in Enfusion or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Enfusion's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Enfusion Trading Alerts and Improvement Suggestions
| Enfusion is unlikely to experience financial distress in the next 2 years | |
| Enfusion has a very strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Enfusion Third Quarter 2024 Earnings Misses Expectations |
Enfusion Returns Distribution Density
The distribution of Enfusion's historical returns is an attempt to chart the uncertainty of Enfusion's future price movements. The chart of the probability distribution of Enfusion daily returns describes the distribution of returns around its average expected value. We use Enfusion price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Enfusion returns is essential to provide solid investment advice for Enfusion.
| Mean Return | 0.35 | Value At Risk | -2.9 | Potential Upside | 3.93 | Standard Deviation | 2.02 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Enfusion historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Enfusion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Enfusion, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Enfusion back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | Next Century Growth Investors Llc | 2024-06-30 | 1.1 M | Geode Capital Management, Llc | 2024-09-30 | 1 M | State Street Corp | 2024-06-30 | 931.2 K | Wellington Management Company Llp | 2024-06-30 | 915.3 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 688.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 580.6 K | Bank Of America Corp | 2024-06-30 | 579.7 K | Impax Asset Management Group Plc | 2024-06-30 | 540 K | Iconiq Capital, Llc | 2024-09-30 | 14 M | Brown Capital Management, Llc | 2024-09-30 | 7.2 M |
Enfusion Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Enfusion or Software sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Enfusion's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Enfusion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.19 | |
β | Beta against Dow Jones | 1.15 | |
σ | Overall volatility | 2.00 | |
Ir | Information ratio | 0.10 |
Enfusion Volatility Alert
Enfusion has relatively low volatility with skewness of 0.23 and kurtosis of 0.3. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enfusion's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enfusion's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Enfusion Fundamentals Vs Peers
Comparing Enfusion's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Enfusion's direct or indirect competition across all of the common fundamentals between Enfusion and the related equities. This way, we can detect undervalued stocks with similar characteristics as Enfusion or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Enfusion's fundamental indicators could also be used in its relative valuation, which is a method of valuing Enfusion by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Enfusion to competition |
| Fundamentals | Enfusion | Peer Average |
| Return On Equity | 0.0548 | -0.31 |
| Return On Asset | 0.0592 | -0.14 |
| Profit Margin | 0.02 % | (1.27) % |
| Operating Margin | 0.06 % | (5.51) % |
| Current Valuation | 910.89 M | 16.62 B |
| Shares Outstanding | 94.37 M | 571.82 M |
| Shares Owned By Insiders | 5.52 % | 10.09 % |
| Shares Owned By Institutions | 96.78 % | 39.21 % |
| Number Of Shares Shorted | 1.02 M | 4.71 M |
| Price To Earning | 0.11 X | 28.72 X |
| Price To Book | 13.42 X | 9.51 X |
| Price To Sales | 4.85 X | 11.42 X |
| Revenue | 174.53 M | 9.43 B |
| Gross Profit | 103.25 M | 27.38 B |
| EBITDA | 21.93 M | 3.9 B |
| Net Income | 9.25 M | 570.98 M |
| Cash And Equivalents | 56.56 M | 2.7 B |
| Cash Per Share | 0.84 X | 5.01 X |
| Total Debt | 15.44 M | 5.32 B |
| Current Ratio | 9.17 X | 2.16 X |
| Book Value Per Share | 0.75 X | 1.93 K |
| Cash Flow From Operations | 25.63 M | 971.22 M |
| Short Ratio | 2.26 X | 4.00 X |
| Earnings Per Share | 0.04 X | 3.12 X |
| Price To Earnings To Growth | 2.35 X | 4.89 X |
| Target Price | 9.61 | |
| Number Of Employees | 1.1 K | 18.84 K |
| Beta | 0.93 | -0.15 |
| Market Capitalization | 945.61 M | 19.03 B |
| Total Asset | 108.97 M | 29.47 B |
| Retained Earnings | (172.93 M) | 9.33 B |
| Working Capital | 49.54 M | 1.48 B |
| Net Asset | 108.97 M |
Note: Acquisition by Somers Deirdre of 13470 shares of Enfusion subject to Rule 16b-3 [view details]
Enfusion Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Enfusion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Enfusion Buy or Sell Advice
When is the right time to buy or sell Enfusion? Buying financial instruments such as Enfusion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Enfusion in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Enfusion Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.04 | Revenue Per Share 2.155 | Quarterly Revenue Growth 0.154 | Return On Assets 0.0592 |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.